|Dr. Paul Alexander Kasian Ph.D.||Exec. Chairman & CEO||N/A||N/A||1957|
|Dr. Jerzy Muchnicki||Exec. Director & Bus. Devel. Director||N/A||N/A||N/A|
|Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI||COO, CFO & Company Sec.||N/A||N/A||N/A|
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Genetic Technologies Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.